CD274 and melanoma: Several works have demonstrated that liquid biopsy analysis (mainly CSF and blood markers) in the context of BM from breast, lung, and melanoma tumors, allow to molecularly characterize the disease taking into account the tumor evolution and heterogeneity and determine the status of well stablished immune biomarkers such as PD-L1, TMB or MSI condition.